Last reviewed · How we verify
RN624
At a glance
| Generic name | RN624 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RN624 In Adult Patients With Chronic Low Back Pain (PHASE2)
- Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip (PHASE3)
- RN624 For Pain Of Post-Herpetic Neuralgia (PHASE2)
- Tanezumab in Osteoarthritis of the Hip or Knee (2) (PHASE3)
- Tanezumab In Osteoarthritis Of The Hip Or Knee (PHASE3)
- Tanezumab In Osteoarthritis Of The Knee (2) (PHASE3)
- Extension Study Of Tanezumab In Osteoarthritis (PHASE3)
- Tanezumab in Osteoarthritis of the Knee (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RN624 CI brief — competitive landscape report
- RN624 updates RSS · CI watch RSS
- Pfizer portfolio CI